Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARCT
DateTimeSourceHeadlineSymbolCompany
26/04/202406:01Business WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/03/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/03/202408:01Business WireArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/02/202401:00Business WireArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
24/02/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
23/02/202400:30Business WireArcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
21/02/202401:00Business WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
06/02/202400:30PR Newswire (US)New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
06/02/202400:30Business WireNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
22/12/202300:00Business WireCSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
22/12/202300:00PR Newswire (US)CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
20/12/202312:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/12/202300:30Business WireArcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
29/11/202300:05PR Newswire (US)Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
29/11/202300:00Business WireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in AdultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/11/202301:13Dow Jones NewsArcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/11/202300:30Business WireArcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
16/11/202300:51IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
15/11/202308:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
15/11/202308:01Business WireArcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/10/202307:01Business WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
24/10/202307:01Business WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/10/202323:30Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/09/202306:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/09/202322:30Business WireArcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/09/202322:30Business WireStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 VariantsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/09/202322:30Business WireArcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
17/08/202322:30Business WireArcturus Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/08/202323:00Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/08/202307:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT